Resverlogix Corp. · TSX:RVX
Resverlogix — Corporate Update (June 2020)
9 slides from Resverlogix's corporate update, Jun 10, 2020
Slide 1: Resverlogix Corp. Corporate Update Conference Call & Webcast
TSX: RVX Resverlogix Corp. Corporate Update Conference Call & Webcast June 10, 2020 at 11 am ET Presented by: Donald J. McCaffrey, President & CEO 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends",
Slide 3: Kaplan-Meier Estimates by CKD/Non-CKD for MACE
Kaplan-Meier Estimates by CKD/Non-CKD for MACE Apabetalone Compared to Placebo CKD Group (eGFR < 60) Apabetalone + Top Standard of Care CKD Group (eGFR<60) Placebo + Top Standard of Care Placebo Events - 35/164 (21.3%) Apabetalone Events - 13/124 (10.5%) Hazard Ratio = 0.50 [95%CIs: 0.26,0.96; p=0.0
Slide 4: Efficacy - The Drug Works!
Efficacy - The Drug Works! Trials confirmed a highly significant reduction in Death, Heart Attacks and CHF. Alternative Endpoint of CV Death, Non-Fatal MI, Stroke and Hospitalization for CHF Patients Receiving SGLT2 or DPP4 Inhibitor Treatment Placebo 25 + Top Standard ofPlacebo Care + Top Standard
Slide 5: Additional Topics to Review
Additional Topics to Review • COVID-19 investigations • Pulmonary Arterial Hypertension Program • US FDA Breakthrough Therapy Designation progress and support • Business Plan and go forward modeling 5
Slide 6: FDA Approves Breakthrough Therapy Designation
FDA Approves Breakthrough Therapy Designation “A breakthrough therapy designation is for a drug that treats a serious or life- threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over availabl
Slide 7: Required Drug Qualities for Successful Commercialization
Required Drug Qualities for Successful Commercialization • Efficacy, does the drug work? • Safety , is the drug safe in general populations? • Regulatory Approvability, will the FDA or EMA approve the drug based on safety and efficacy? • Mechanism of Action (MOA) , a deep understanding of how
Slide 8: Strategic Commercial Pathway - Global Vascular Opportunity
Strategic Commercial Pathway - Global Vascular Opportunity Apabetalone is a first-in-class, small molecule that is a selective BET inhibitor that produces a specific set of biological effects with important benefits while maintaining a well described safety profile. It is currently being evaluated f
Slide 9: Resverlogix Corp. Contact
TSX: RVX Resverlogix Corp. Corporate Update Conference Call & Webcast June 10, 2020 at 11 am ET Contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Website: www.resverlogix.com 9